Docetaxel emulsion - Savara Pharmaceuticals
Alternative Names: ANX-514; BTH-014; Polysorbate 80-free formulation of docetaxel - Savara Pharmaceuticals; SDP-014Latest Information Update: 18 Dec 2021
Price :
$50 *
At a glance
- Originator ADVENTRX Pharmaceuticals
- Developer Mast Therapeutics
- Class Antineoplastics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Apr 2017 Mast Therapeutics merged with Savara Pharmaceuticals and will operate under the name Savara Pharmaceuticals
- 11 Mar 2013 ADVENTRX is now called Mast Therapeutics
- 31 Dec 2012 Discontinued - Phase-I for Cancer in Argentina (IV)